Elevated phosphorylated α-synuclein and phosphorylated tau in Lrrk2 p.G2019S-mutant mice following influenza A pneumonitis
While influenza A pneumonitis did not alter acute sickness outcomes in mice, homozygous Lrrk2 p.G2019S mutants exhibited significantly elevated brain levels of phosphorylated α-synuclein, phosphorylated tau, and oxidative stress markers six weeks post-infection, suggesting that this specific mutation may predispose individuals to infection-triggered neurodegenerative changes.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Parkinson's disease is a condition that slowly erodes the brain's ability to control movement, often leaving its exact origins a mystery. Scientists believe it arises from a complex mix of inherited genetic risks and environmental triggers, such as infections, that strike later in life. One of the most significant genetic risk factors involves a gene called LRRK2. While most people carry two normal copies of this gene, some individuals carry a specific mutation that makes the protein it produces overly active. This mutation is found in a small percentage of people with Parkinson's, yet many carriers never develop the disease, suggesting that a second event, perhaps a viral infection, might be needed to set the illness in motion. Influenza, the virus that causes the flu, has long been suspected as a potential trigger; historical records show that severe flu outbreaks have sometimes been followed by a rise in Parkinson's-like symptoms, hinting that a respiratory infection could somehow damage the brain long after the fever has broken.
To test this idea, researchers at the University of Ottawa and their collaborators turned to mice, using a strain of the influenza A virus that causes severe lung infection but does not naturally infect the brain. They focused on adult mice that carried the same LRRK2 mutation found in humans, specifically a version that makes the protein hyperactive. The team inoculated these mice with a dose of the virus strong enough to kill about half of them, while also infecting mice with normal genes and a different group with a mutation that completely shuts down the protein's activity. The goal was to see if the genetic differences changed how the mice fought the infection in their lungs, and more importantly, to check what happened inside their brains weeks after they survived the illness.
The results showed that the genetic makeup of the mice did not change their immediate battle with the flu. Whether the mice had the hyperactive mutation, the inactive mutation, or normal genes, they suffered the same weight loss, faced the same risk of death, and carried similar amounts of virus in their lungs during the acute phase of the infection. The virus did not behave differently in the lungs of the genetically altered mice, and the animals' immune systems responded in much the same way regardless of their genetic background. This finding ruled out the idea that the mutation simply made the mice better or worse at fighting off the initial lung infection.
However, the story changed dramatically once the mice recovered and were observed for six weeks after the infection. When the researchers examined the brains of the survivors, they found that the mice with the hyperactive mutation had suffered silent, chemical changes that the other mice did not. In these specific animals, the brain showed a significant rise in oxidative stress, a state where harmful molecules accumulate and can damage cells. More notably, the brains contained higher levels of two specific proteins that are hallmarks of Parkinson's disease: a form of alpha-synuclein and a form of tau that had been chemically altered. These altered proteins are known to clump together in the brains of people with Parkinson's, disrupting cell function. The mice with normal genes, even after surviving the same severe lung infection, did not show these same chemical shifts in their brains.
The researchers also looked at a version of the mice where the LRRK2 protein was completely inactive. In these animals, the infection did not lead to the same rise in oxidative stress seen in the wild-type mice, suggesting that the protein's activity level plays a crucial role in how the brain reacts to peripheral infections. The study suggests that while the flu virus itself stays in the lungs, the body's intense reaction to it can send signals to the brain that trigger these damaging chemical changes, but only in individuals who already carry the specific genetic risk factor. This provides a plausible explanation for why some people with the LRRK2 mutation develop Parkinson's while others do not; they may need a specific environmental hit, like a severe respiratory infection, to unlock the disease. The findings do not prove that the flu causes Parkinson's in humans, but they offer a clear, concrete mechanism showing how a lung infection can leave a lasting, damaging mark on the brain in the presence of a specific genetic vulnerability.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.